Neuroblastoma: a neurochemical approach.
Neuroblastoma is among the most common malignancies of childhood. Despite greatly improved therapy for some pediatric tumors, the prognosis for children with metastatic neuroblastoma has not changed significantly in the past 10 years. With conventional chemotherapy, radiation therapy, and surgery, children with metastatic neuroblastoma have a 20% long-term survival rate. We describe here approaches to neuroblastoma that target its neuronal characteristics. On the one hand, the neurotransmitter receptors on the surface of the neuroblastoma cells and, on the other hand, specific isozymes that distinguish neuroblastoma cells from their normal counterparts are the focus of these experimental therapies. In the former case, specificity for tumor cells is effected by (1) selective protection of normal neuronal elements from toxicity, or (2) selective potentiation of toxicity for neural tumor cells. It is hoped that these strategies will be generalizable to other neural crest-derived tumors.
Schor
N F
NF
Department of Pediatrics, Children's Hospital of Pittsburgh, PA 15213.
D004999:Amifostine / Q000627:therapeutic use*; D000818:Animals; D004298:Dopamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004357:Drug Synergism; D006892:Hydroxydopamines / Q000627:therapeutic use*; D051379:Mice; D009423:Nervous System Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D009432:Neural Crest; D009447:Neuroblastoma / Q000188:drug therapy* / Q000503:physiopathology; D009353:Zinostatin / Q000627:therapeutic use*
C024710:6-mercaptodopamine; D006892:Hydroxydopamines; D009353:Zinostatin; D004999:Amifostine; D004298:Dopamine